Q2 2025 · 13F-HR
Stonepine Capital Management, LLCholdings as filed
Filed 2025-08-13 · accession 0000935836-25-000497
$101.9M
Reported value
59
Positions
2025-06-30
Period end
The Brief · Stonepine Capital Management, LLC · Q2 2025
AI · grounded in 13F
Stonepine Capital Management, LLC established a new position in ADMA valued at $13.66M. The fund also initiated new stakes in EOLS for $8.44M and ZVRA for $6.83M. Additional new positions include VSTM at $6.06M and INDV at $5.16M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 000899104 | ADMA | ADMA BIOLOGICS INC | $13.7M | 13.4% | 750,000 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $8.4M | 8.28% | 916,500 | Common | SOLE |
| 488445206 | ZVRA | ZEVRA THERAPEUTICS INC | $6.8M | 6.70% | 775,620 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $5.6M | 5.54% | 1,360,386 | Common | SOLE |
| G4766E116 | INDV | INDIVIOR PLC | $5.2M | 5.06% | 350,000 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $4.9M | 4.76% | 225,000 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $4.6M | 4.48% | 604,066 | Common | SOLE |
| 872381108 | TELA | TELA BIO INC | $4.0M | 3.97% | 2,083,762 | Common | SOLE |
| 98419J206 | XOMA | XOMA ROYALTY CORPORATION | $3.8M | 3.76% | 152,143 | Common | SOLE |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $3.1M | 3.03% | 310,033 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $2.9M | 2.87% | 450,000 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $2.7M | 2.68% | 306,029 | Common | SOLE |
| 00182C103 | ANIP | ANI PHARMACEUTICALS INC | $2.5M | 2.47% | 38,597 | Common | SOLE |
| 039697107 | ARDX | ARDELYX INC | $2.2M | 2.13% | 555,000 | Common | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $2.0M | 1.98% | 190,590 | Common | SOLE |
| 054754858 | AYTU | AYTU BIOPHARMA INC | $1.8M | 1.74% | 812,676 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $1.4M | 1.40% | 733,793 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $1.4M | 1.38% | 1,000,000 | Common | SOLE |
| 427746102 | HRTX | HERON THERAPEUTICS INC | $1.4M | 1.34% | 657,380 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $1.3M | 1.27% | 50,200 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $1.3M | 1.26% | 285,300 | Common | SOLE |
| 19459J104 | COLL | COLLEGIUM PHARMACEUTICAL INC | $1.2M | 1.20% | 41,500 | Common | SOLE |
| 921659108 | VNDA | VANDA PHARMACEUTICALS INC | $1.2M | 1.16% | 250,000 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $1.1M | 1.11% | 100,000 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $1.0M | 1.03% | 349,615 | Common | SOLE |
| 62857J201 | MYO | MYOMO INC | $988,025 | 0.97% | 457,419 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $976,740 | 0.96% | 219,000 | Common | SOLE |
| 98422E103 | XERS | XERIS BIOPHARMA HOLDINGS INC | $957,817 | 0.94% | 205,100 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $896,726 | 0.88% | 845,968 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $870,009 | 0.85% | 92,900 | Common | SOLE |
| 00439U104 | GRCE | GRACE THERAPEUTICS INC | $868,725 | 0.85% | 292,500 | Common | SOLE |
| 49372L209 | 2KZ0 | KEZAR LIFE SCIENCES INC | $777,954 | 0.76% | 169,859 | Common | SOLE |
| 03475V101 | ANGO | ANGIODYNAMICS INC | $765,239 | 0.75% | 77,141 | Common | SOLE |
| 004468500 | ACHV | ACHIEVE LIFE SCIENCES INC | $753,333 | 0.74% | 333,333 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $697,646 | 0.68% | 491,300 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $655,200 | 0.64% | 130,000 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $623,981 | 0.61% | 151,085 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $623,000 | 0.61% | 50,000 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $577,164 | 0.57% | 544,494 | Common | SOLE |
| 49721T507 | KPRX | KIORA PHARMACEUTICALS INC | $512,640 | 0.50% | 178,000 | Common | SOLE |
| 84833T103 | SPRO | SPERO THERAPEUTICS INC | $454,975 | 0.45% | 156,888 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $449,758 | 0.44% | 226,009 | Common | SOLE |
| 88338H704 | TQ80 | THERATECHNOLOGIES INC | $446,160 | 0.44% | 189,051 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $415,000 | 0.41% | 100,000 | CALL | SOLE |
| 745848101 | LUNG | PULMONX CORP | $377,881 | 0.37% | 145,900 | Common | SOLE |
| 42225T107 | HCAT | HEALTH CATALYST INC | $377,000 | 0.37% | 100,000 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HLDGS INC | $298,970 | 0.29% | 7,000 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $297,600 | 0.29% | 30,000 | Common | SOLE |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $255,600 | 0.25% | 45,000 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $193,800 | 0.19% | 85,000 | Common | SOLE |
| 45674E208 | INAB | IN8BIO INC | $172,279 | 0.17% | 82,430 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $166,335 | 0.16% | 85,300 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $144,250 | 0.14% | 25,000 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $144,022 | 0.14% | 116,147 | Common | SOLE |
| 38942Q202 | CALC | CALCIMEDICA INC | $136,000 | 0.13% | 85,000 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $135,300 | 0.13% | 30,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS LLC | $126,452 | 0.12% | 109,010 | Common | SOLE |
| 10170A100 | BOLD | BOUNDLESS BIO INC | $107,237 | 0.11% | 106,175 | Common | SOLE |
| 19249H103 | CHRS | COHERUS BIOSCIENCES INC | $45,853 | 0.04% | 62,700 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.